Valiltramiprosate
A drug candidate for Alzheimer's disease
| Valiltramiprosate | |
|---|---|
| File:Valiltramiprosate.svg | |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | 157604-28-1 |
| PubChem | 6918636 |
| DrugBank | |
| ChemSpider | 5293734 |
| KEGG | D08895 |
Valiltramiprosate is a drug candidate that was investigated for the treatment of Alzheimer's disease. It is a derivative of tramiprosate, which is a compound that was initially studied for its potential to inhibit the aggregation of amyloid-beta peptides, a hallmark of Alzheimer's pathology.
Chemical Structure and Properties[edit]
Valiltramiprosate is chemically known as (2S)-2-amino-3-(3-methylbutanoylamino)propanoic acid. It is a small molecule with the molecular formula C9H18N2O3. The compound is characterized by the presence of an amino acid backbone with a valine moiety, which is thought to enhance its ability to interact with amyloid-beta peptides.
Mechanism of Action[edit]
Valiltramiprosate is designed to interfere with the aggregation of amyloid-beta peptides into plaques, which are believed to play a critical role in the pathogenesis of Alzheimer's disease. By preventing or reducing the formation of these plaques, Valiltramiprosate aims to slow down the progression of the disease and alleviate cognitive symptoms.
Clinical Development[edit]
Valiltramiprosate was developed following the initial studies on tramiprosate, which showed some promise in preclinical models. However, clinical trials of tramiprosate did not demonstrate significant efficacy in patients with Alzheimer's disease. Valiltramiprosate was subsequently developed as a modified version with potentially improved pharmacokinetic properties.
Challenges and Future Directions[edit]
The development of Valiltramiprosate, like many other Alzheimer's treatments, faces significant challenges. The complexity of Alzheimer's disease, with its multifactorial etiology, makes it difficult to target a single pathway effectively. Future research may focus on combination therapies that target multiple aspects of the disease simultaneously.
Related Pages[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
- Budget GLP-1 shots
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
